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I. GENERAL INTRODUCTION 
Cognitive deficits in patients of psychiatric disorders including schizophrenia and 
major depressive disorder are recognized as a serious social problem in recent years. 
Especially in schizophrenia, it is thought that cognitive deficits are not epiphenomena 
arising from positive and negative symptoms but one of the main symptoms of 
schizophrenia. The Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) developed by the US National Institute of Mental Health 
(NIMH) defined that there are several main cognitive domains easily impaired by 
schizophrenia such as attention/vigilance, working memory, verbal learning and 
memory, visual learning and memory, reasoning and problem solving, speed of 
processing and social cognition (Table 1).  
 
Cognitive domains Example 
attention/vigilance ability to response appropriately to series of stimuli appeared 
quickly 
ex) reading book, watching movie  
working memory ability to memorize information for short-time (about 5-20 
seconds) and process it 
ex) memorizing phone number newly taught  
verbal learning  
verbal memory 
ability to memorize verbal information for long-time (a few 
minutes- a few years) 
ex) memorizing someone’s request to buy in the store 
visual learning  
visual memory 
ability to memorize visual information for long-time (a few 
minutes- a few years) 
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ex) memorizing what and where to store 
reasoning  
problem solving 
ability to carry out a project effectively 
ex) getting workplace in time despite of changing time of the 
usual bus  
speed of processing ability to process the information exactly and response it 
quickly 
 ex) serving a customer with touch panel operation 
social cognition ability to process and memorize social information such as 
expressions, emotions and meaning of social interaction 
ex) memorizing someone’s face or ability of recognizing 
someone’s feeling from his/her expression 
Table 1. Cognitive domains impaired in patients with schizophrenia 
 
 These cognitive domains are necessary for working. Therefore cognitive deficits 
constitute a major cause of low employment rate in patients of psychiatric disorders 
(Mueser et al, 2002). Social isolation by disemployment might decrease patient’s 
motivation, and has possibility to result in worsening of symptoms. Additionally, 
cognitive deficits cause a decrease in the drug adherence rate of patients and might 
prevent improvement of symptoms (Patterson et al, 2002). Treatment for cognitive 
deficits is needed for not only improvement of cognitive deficits itself, but also 
improvement of other symptoms of psychiatric disorders. There is no antipsychotic drug 
having enough therapeutic effect for cognitive deficits despite of challenging for 
development of novel drugs. Development of effective drugs for cognitive deficits is 
critically-needed by psychiatric patients.  
3 
 
 
Brexpiprazole , 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy} 
quinolin-2(1H)-one (Figure 1) , is a novel serotonin-dopamine activity modulator 
developed within recent years. Brexpiprazole has higher serotonin 5-HT1A receptor and 
dopamine D2 receptor binding affinity than an atypical antipsychotic drug, aripiprazole 
(Figure 1, Table 2). Brexpiprazole has a slightly higher binding affinity for h5-HT1A 
receptors than hD2 receptors, whereas aripiprazole has reverse effect (Table 2). 
Additionally, the inhibitory activity for hD2L receptor on brexpiprazole was a little 
weaker than that on aripiprazole which indicates that the intrinsic activity for D2 on 
brexpiprazole is slightly lower than that on aripiprazole (Figure 2). As brexpiprazole 
has lower intrinsic activity at D2 receptor compared with aripiprazole, it can expect to 
have fewer adverse effects by D2 receptor agonism and antagonism than aripiprazole. It 
is also an antagonist at 5-HT2A receptors and adrenergic α1B/2C receptors (Maeda et al., 
2014a). The 5-HT1A receptor agonism is focused on the ability for improvement of 
several clinical and non-clinical reports.  
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      Figure 1. Chemical structure of brexpiprazole and aripiprazole 
 
 
 
 
 
 
 
 
 
 
 
a
Data from Maeda et al., 2014a. 
b
Data from Shapiro et al., 2003. 
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Table 2. Binding affinities for cloned human receptors in vitro (Maeda et al. 2014a) 
Data are calculated by nonlinear regression analysis using data from three assays performed in 
duplicate or triplicate and expressed as mean values. 
 
 
 
 
Figure 2. Partial agonist activity of brexpiprazole and reference drugs on human 
cloned D2L receptors in vitro (Maeda et al. 2014a) 
Concentration-response curves are shown for brexpiprazole and aripiprazole on forskolin induced 
cAMP accumulation in hD2L receptor–expressing CHO cells. Data are mean 6 S.D. of three assays 
performed in duplicate. Cyclic AMP accumulation was normalized to the percentage of 
forskolin-induced cAMP accumulation (set at 100%). 
 
The research in animal model reflecting clinical cognitive deficits is critically important 
to evaluate the effects of drugs. However, there is no unified classification whether 
which animal model for testing cognitive deficits match which domains in listed in 
Table 1. Multiple testing for one drug can resolve this problem. 
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In the present study, we investigated the therapeutic effects of a novel 
antipsychotic drug brexpiprazole on social recognition impaired by the 
N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine, and cognitive deficits 
in mice after administration of the NMDA receptor antagonist phencyclidine (PCP). We 
divided our study into the following two chapters. 
 
CHAPTER 1 
We investigated the effects of brexpiprazole, olanzapine and risperidone, on 
dizocilpine-induced social recognition impairment, in mice. Furthermore, we also 
investigated the effect of brexpiprazole, olanzapine, and risperidone on social 
recognition, in untreated mice. Moreover, we investigated the role of serotonin 5-HT1A 
receptor on the effect of brexpiprazole on dizocilpine-induced social recognition 
impairment. 
 
CHAPTER 2 
Using the novel object recognition test (NORT), we investigated the effects of 
subsequent subchronic brexpiprazole on PCP -induced cognitive deficits in mice. 
Furthermore, we investigated the role of 5-HT1A receptor on the effect of brexpiprazole 
in this model. 
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measure in older outpatients with schizophrenia. Journal of clinical 
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Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L.X., Sibley, D.R., Roth, 
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unique and robust pharmacology. Neuropsychopharmacology : official 
publication of the American College of Neuropsychopharmacology 28, 
1400-1411. 
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II. CHAPTER 1 
Improvement of dizocilpine-induced social recognition deficits in mice by 
brexpiprazole, a novel serotonin-dopamine active modulator  
 
1. ABSTRACT 
Cognitive impairment, including impaired social cognition, is largely responsible for the 
deterioration in social life suffered by patients with psychiatric disorders, such as 
schizophrenia and major depressive disorder (MDD). Brexpiprazole 
(7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one), a novel 
serotonin-dopamine activity modulator, was developed to offer efficacious and tolerable 
therapy for different psychiatric disorders, including schizophrenia and adjunctive 
treatment of MDD. In this study, we investigated whether brexpiprazole could improve 
social recognition deficits (one of social cognition deficits) in mice, after administration 
of the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 (dizocilpine). 
Dosing with dizocilpine (0.1 mg/kg) induced significant impairment of social 
recognition in mice. Brexpiprazole (0.01, 0.03, 0.1 mg/kg, p.o.) significantly 
ameliorated dizocilpine-induced social recognition deficits, without sedation or a 
reduction of exploratory behavior. In addition, brexpiprazole alone had no effect on 
social recognition in untreated control mice. By contrast, neither risperidone (0.03 
mg/kg, p.o.) nor olanzapine (0.03 mg/kg, p.o.) altered dizocilpine-induced social 
recognition deficits. Finally, the effect of brexpiprazole on dizocilpine-induced social 
recognition deficits was antagonized by WAY-100,635, a selective serotonin 5-HT1A 
antagonist. These results suggest that brexpiprazole could improve dizocilpine-induced 
social recognition deficits via 5-HT1A receptor activation in mice. Therefore, 
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brexpiprazole may confer a beneficial effect on social cognition deficits in patients with 
psychiatric disorders. 
 
2. INTRODUCTION 
Cognitive impairment describes a diverse range of deficits, seen in psychiatric 
disorders.  Of these, impaired social cognition greatly hampers everyday life, resulting 
in poor work productivity or underemployment of patients with schizophrenia and 
major depressive disorder (MDD) (Tandberg et al, 2011; Tse et al, 2013; Horan et al, 
2012; Lo and Siu, 2014). It is generally accepted that reducing social cognitive 
dysfunction is an important factor in assisting psychiatric patients to make healthy 
adjustments in their social lives (Tandberg et al, 2011; Tse et al, 2013; Horan et al, 
2012; Trapp et al, 2013). Current reports suggest that training of social cognition may 
help to improve functional outcome in patients with schizophrenia (Henderson, 2013). 
To complement this, the development of novel drugs to improve social cognition 
deficits in patients with schizophrenia is also imperative. 
Social recognition testing is designed to measure the propensity of a mouse to 
make contact with a novel rather than familiar mouse. This testing therefore represents a 
cognitive model that reflects innate ability to communicate with others (Moy et al, 
2004; van der Kooij and Sandi, 2012). Social recognition test in rodents is also one of 
the assays for evaluating social cognition in humans (Millan and Bales, 2013). Based on 
the N-methyl-D-aspartate (NMDA) hypofunction hypothesis of schizophrenia 
(Hashimoto, 2006; 2014; Hashimoto et al, 2013), the NMDA receptor antagonist, 
(+)-MK-801 (dizocilpine), is widely used to induce schizophrenia-like behavioral 
abnormalities, including positive and negative symptoms and cognitive deficits in 
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rodents (Hashimoto et al, 2009; Karasawa et al, 2008; Rajagopal et al, 2013; Meltzer et 
al, 2011; Okamura et al, 2004; Rogoz, 2013; Zhang et al, 2007). Furthermore, 
dizocilpine also impairs social interaction and social recognition (Maehara et al, 2011; 
Oh et al, 2013; Hikichi et al, 2013). 
Brexpiprazole, 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy} 
quinolin-2(1H)-one, is a novel serotonin-dopamine activity modulator with high affinity 
for serotonin, dopamine and noradrenaline receptors (Maeda et al, 2014a). It is a partial 
agonist at serotonin 5-HT1A and dopamine D2 receptors, with a relatively equal potency, 
and an antagonist at 5-HT2A receptors and adrenergic α1B/2C receptors. Brexpiprazole is 
currently under clinical evaluation and expected to show efficacy and tolerability when 
used as therapy for different psychiatric disorders, including schizophrenia and 
adjunctive treatment for MDD. Very recently, brexpiprazole was shown to improve the 
NMDA receptor antagonist phencyclidine-induced cognitive deficits in the novel object 
recognition test in rodents (Maeda et al, 2014b; Yoshimi et al, 2014). To date, the effect 
of brexpiprazole on social recognition has not been investigated. In this study, we 
evaluated the effects of brexpiprazole on dizocilpine-induced social recognition deficits 
in mice. 
 
3. EXPERIMENTAL PROCEDURES 
3.1. Animals 
Male C57BL/6NCrSlc mice (Japan SLC Inc., Shizuoka, Japan) aged between 4 
and 5 weeks old were selected as stranger mice, while animals between 8 and 10 weeks 
old were used for this study. All mice were housed in groups of five per cage, in a room 
maintained at 23 ± 2 °C and 60 ± 10 % humidity, with a 12/12 hour light/dark cycle 
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(lights on at 7:00 a.m.). The mice were given free access to food and water. Animal care 
and use were conducted in accordance with the Institutional Guidelines for Animal Care 
and Use (Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan). 
3.2. Drugs 
(+)-MK-801 hydrogen maleate (dizocilpine) was purchased from Sigma-Aldrich 
Co., Ltd (Tokyo, Japan). Brexpiprazole, risperidone, olanzapine and WAY-100,635 
were synthesized at Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan). Dizocilpine was 
dissolved in saline and administered intraperitoneally (i.p.) at 10 ml/kg, twice daily, on 
the day before and 30 minutes prior to sociability testing. Brexpiprazole, risperidone, 
olanzapine and WAY-100,635 were dissolved in 5% (w/v) gum Arabic and 
administered orally (p.o.), at 10 ml/kg, 1 hour prior to sociability testing. The doses of 
dizocilpine (0.1 mg/kg) and WAY-100,635 (1.0 mg/kg) were selected from previously 
published reports in mice (Hagiwara et al, 2008; Hashimoto et al, 2009; Takatsu et al, 
2011; Yoshimi et al, 2014; Zhang et al, 2007). The doses of antipsychotic drugs were 
selected based on doses that did not impact locomotion (data not shown). 
3.3. Apparatus 
The test apparatus consisted of a rectangular, three-chambered box, and a lid with 
an attached infrared video camera (O’Hara & Co., Tokyo, Japan). The apparatus was 
610W x 400D x 220H mm, and the dividing walls were made from clear Plexiglass, 
with small square openings (3 x 5 cm) allowing access into each chamber. The stranger 
mouse was enclosed in a small, round wire cage (diameter, 10 cm; height, 12 cm), 
allowing olfactory, visual, auditory, and tactile contact, but no deep contact. Using a 
CCD camera, measures were taken of the amount of time spent around the wire cage. 
The total distance traveled was calculated based on traced mice movement and 
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presented as the locomotor activity in this study. All data were computerized. Activity 
was monitored and analyzed using applications based on the public domain NIH Image 
or Image J program (developed by Wayne Rasband at the U.S. National Institute of 
Mental Health and available on the Internet at http://rsb.info.nih.gov/nih-image/) 
(O’Hara & Co., Tokyo, Japan). 
3.4. Behavioral procedures 
The measurement of sociability and social recognition was performed using the 
same procedure described in previous reports (Moy et al, 2007; Nakatani et al, 2009; 
Matsuo et al, 2009; Riedel et al, 2009). In this study, we focused on a narrowly defined 
set of parameters. 
3.4.1. Habituation 
Mice were randomly assigned to groups. Mice were first placed in the middle 
compartment of the apparatus and allowed to explore freely for 6 minutes. All other 
compartments were empty during this habituation period. 
3.4.2. Sociability test 
An unfamiliar male (stranger) that had no prior contact with the mouse was placed 
in one of the side chambers. After the habituation period, the unfamiliar male juvenile 
mouse (stranger 1) was placed inside the round wire cage, in one of the side 
compartments (randomly selected and counterbalanced for each group). The opposite 
compartment was empty. The mice were able to freely explore all three compartments 
of the apparatus for 6 minutes. The time spent around cages (stranger 1 or empty) was 
calculated as direct contact. 
3.4.3. Social recognition test 
After sociability testing, a novel unfamiliar juvenile mouse (stranger 2) was 
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placed inside a new round wire cage and introduced to the ‘empty compartment’ of the 
apparatus. Mice were confined to the central compartment and were able to explore 
freely in all compartments for 10 min. 
The recognition index (RI) was calculated using parameters measured during 
social recognition sessions and was defined as the quotient of the time the mouse spent 
around the novel juvenile (stranger 2) divided by the sum of the time spent around the 
familiar (stranger 1) and novel (stranger 2) juvenile mice. 
3.5. Statistical analyses 
All statistical analyses were performed using Prism 5 (GraphPad Software Inc., La 
Jolla, USA). Data are presented as mean ± standard error of the mean (S.E.M.). To 
determine the effects of drug treatment, one-way ANOVA, followed by the post hoc 
Bonferroni test (for RI and total distance) or a two-tailed paired t-test (for RI and time 
spent around cage), was used. P values of less than 0.05 were considered statistically 
significant. 
 
4. RESULTS 
4.1 Effects of brexpiprazole on dizocilpine-induced social recognition deficits  
Mice in all groups spent significantly more time around stranger 1, than the empty 
area in sociability sessions (data not shown). A one-way ANOVA on RI in social 
recognition session showed a significant effect of treatment (F (4, 56) = 5.83, p < 
0.001)(Figure 1A). Saline-treated control mice had a significant preference for 
spending more time with the novel unfamiliar stranger 2, in comparison with familiar 
stranger 1, in the social recognition session (Figure 1B). Treatment with dizocilpine 
(0.1 mg/kg, i.p.) significantly decreased the total time spent around stranger 2 in social 
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recognition sessions. A paired t-test showed a significant (p < 0.01) impairment of RI in 
the dizocilpine-treated group. Mice spent the same amount of time interacting with 
stranger 1 and stranger 2 mice (Figure 1A, and 1B). The total distance moved 
(exploratory behavior), indicative of locomotor activity, was significantly increased by 
dizocilpine administration (Figure 1C).  
Next, we examined whether brexpiprazole attenuated dizocilpine-induced social 
recognition deficits in mice. Neither dizocilpine (0.1 mg/kg, i.p.) nor brexpiprazole 
(0.01, 0.03 and 0.1 mg/kg, p.o) altered the amount of time spent around stranger 1 mice 
in sociability sessions (data not shown). However, at all three doses of brexpiprazole, 
mice treated with brexpiprazole showed a significant preference for spending more time 
with novel unfamiliar stranger 2 mice, compared with familiar stranger 1 mice in social 
recognition sessions (Figure 1B), and additionally, impaired RI was significantly 
restored by treatment with brexpiprazole at the same doses used in sociability testing 
(Figure 1A). Furthermore, brexpiprazole (0.01, 0.03 and 0.1 mg/kg) did not temper the 
increased locomotor activity induced by dizocilpine in social recognition sessions 
(Figure 1C).  
4.2 Brexpiprazole alone did not affect social recognition or exploratory behavior 
We examined the effect of brexpiprazole on social recognition in untreated control 
mice. Treatment with brexpiprazole (0.01, 0.03 and 0.1 mg/kg) had no effect on the 
time spent around stranger 1 mice in either sociability (data not shown) or social 
recognition sessions (Figure 1D, and 1E). Brexpiprazole did not alter RI in social 
recognition sessions (Figure 1D), nor did it have an effect on exploratory behavior 
during either session (Figure 1F).  
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Figure 1. Effects of brexpiprazole on dizocilpine-induced social recognition 
deficits 
Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg, i.p.) was administered twice daily on the day 
before and 30 minutes prior to sociability testing. Brexpiprazole (0.01, 0.03, 0.1 mg/kg, p.o.) or 
vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 hour prior to sociability testing. (A) 
Social recognition was measured by the recognition index (RI), that is, the quotient of time the 
subject mouse spent around the novel juvenile (stranger 2) mouse divided by the sum of the time 
spent around the familiar (stranger 1) and novel juvenile (stranger 2) mice during social 
recognition sessions. (B) Duration of time spent around each stranger during the social 
recognition sessions and, (C) exploratory behavior during social recognition sessions. Values are 
the mean  S.E.M (n = 11-15). *p < 0.05, **p < 0.01, ***p < 0.001 compared with dizocilpine + 
vehicle group (A and C, one-way ANOVA, followed by post hoc Bonferroni test). **p < 0.01, 
***p < 0.001 compared with stranger 1 mice (B, two-tailed paired t-test). Brexpiprazole (0.01, 
0.03, 0.1 mg/kg, p.o.) or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 hour prior to 
sociability testing. The effects of brexpiprazole on the RI (D), duration of time spent around each 
stranger mouse (E), and exploratory behavior (F), during social recognition sessions. Values are 
the mean  S.E.M (n = 7-14). *p < 0.05, **p < 0.01, ***p < 0.001 compared with stranger 1 (E, 
two-tailed paired t-test). N.S.: not significant. 
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4.3 Risperidone and olanzapine had no effect on dizocilpine-induced social 
recognition deficits  
We examined whether the atypical antipsychotic drugs, risperidone and 
olanzapine, affected dizocilpine-induced social recognition deficits in mice. A one-way 
ANOVA on RI in social recognition session showed a significant effect of treatment (F 
(2, 31) = 4.60, p < 0.05)(Figure 2A). Pot-hoc analysis showed that risperidone (0.03 
mg/kg, p.o.) did not ameliorate dizocilpine-induced social recognition deficits (Figure 
2A, 2B), and dizocilpine-induced hyperlocomotion in the recognition sessions (Figure 
2C). When administered alone, risperidone (0.03 mg/kg, p.o.) significantly decreased 
both RI and locomotor activity in untreated control mice (Figure 2D, 2E, and 2F).  
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 A one-way ANOVA on RI in social recognition session showed a significant 
effect of treatment (F (2, 27) = 7.72, p < 0.01)(Figure 3A). Post-hoc analysis showed that 
olanzapine (0.03 mg/kg, p.o.) did not affect time spent around stranger 2 mice, nor did it 
reverse dizocilpine-induced impairment of the RI (Figure 3A, and 3B). Furthermore, 
olanzapine had no effect on dizicilpine-induced hyperlocomotion in the recognition 
sessions (Figure 3C). Olanzapine (0.03 mg/kg, p.o.) alone was incapable of altering RI, 
the time spent around stranger 2 mice, or exploratory behavior in untreated control mice 
(Figure 3D, 3E, and 3F).  
 
Figure 2. Effect of risperidone on dizocilpine-induced social recognition deficits 
Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg, i.p.) was administered twice daily on the day 
before and 30 minutes prior to sociability testing. Risperidone (0.03 mg/kg, p.o.) or vehicle (5% 
(w/v) gum Arabic, p.o.) was administrated 1 hour prior to sociability testing. The effects of 
risperidone on RI (A), duration of time spent around each stranger mouse (B), and exploratory 
behavior (C) during social recognition sessions. Values are the mean  S.E.M (n = 11 or 12). *p 
< 0.05 compared with dizocilpine + vehicle group (A and C, one-way ANOVA, followed by post 
hoc Bonferroni test). N.S.: not significant. **p < 0.01 compared with stranger 1 mice (B, 
two-tailed paired t-test). Risperidone (0.03 mg/kg, p.o.) or vehicle (5% (w/v) gum Arabic, p.o.) 
was administrated 1 hour prior to sociability testing. The effects of risperidone on RI (D), 
duration of time spent around each stranger mouse (E) and exploratory behavior (F) during 
social recognition sessions. Values are the mean  S.E.M (n=7). *p < 0.05 compared with the 
vehicle-treated control group (D and F, two-tailed paired t-test). *p < 0.05, ***p < 0.001 
compared with stranger 1 mice (E, two-tailed paired t-test). 
18 
 
 
 
 Figure 3. Effect of olanzapine on dizocilpine-induced social recognition deficits  
Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg, i.p.) administered twice daily on the day before 
and 30 minutes prior to sociability testing. Olanzapine (0.03 mg/kg, p.o.) or vehicle (5% (w/v) 
gum Arabic, p.o.) was administrated 1 hour prior to sociability testing. The effects of olanzapine 
on RI (A), duration of time spent around each stranger mouse (B) and exploratory behavior (C) 
during social recognition sessions. Values are the mean  S.E.M (n=10). **p < 0.01, ***p < 
0.001 compared with vehicle-treated control group for (A) and (C) (one-way ANOVA, followed 
by post hoc Bonferroni test). ***p < 0.001 compared with stranger 1 mice for (B) (two-tailed 
paired t-test). Olanzapine (0.03 mg/kg, p.o.) or vehicle (5% (w/v) gum Arabic, p.o.) was 
administrated 1 hour prior to sociability testing. The effects of olanzapine on RI (D), duration of 
time spent around each stranger mouse (E) and exploratory behavior (F) during social 
recognition sessions. Values are the mean  S.E.M (n=7). **p < 0.01, ***p < 0.001 compared 
with stranger 1 mice for (E) (two-tailed paired t-test). N.S.: not significant. 
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4.4 Role of the 5-HT1A receptor in brexpiprazole's effects on dizocilpine-induced 
social recognition deficits 
To investigate the function of serotonin 5-HT1A receptors in the pharmacological 
effect of brexpiprazole on dizocilpine-induced social recognition deficits, we examined 
the effect of WAY-100,635, a selective 5-HT1A receptor antagonist. A one-way 
ANOVA on RI in social recognition session showed a significant effect of treatment (F 
(4, 57) = 7.82, p < 0.0001)(Figure 4A). Post-hoc analysis showed that WAY-100,635 (1.0 
mg/kg, p.o.) significantly antagonized the effect of brexpiprazole on 
dizocilpine-induced social recognition deficits (Figure 4A, and 4B). Treatment with 
WAY-100,635 alone did not alter RI and locomotion in dizocilpine-treated mice 
(Figure 4A, and 4C). Furthermore, treatment with WAY-100,635 alone did not affect 
RI, the time spent around stranger 2 mice, or exploratory behavior in untreated control 
mice (Figure 4D, 4E and 4F).  
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Figure 4. Effect of a 5-HT1A antagonist on brexpiprazole's action in the 
dizocilpine-induced social recognition deficits model 
Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg, i.p.) was administered twice daily on the day 
before and 30 minutes prior to sociability testing. Brexpiprazole (Brex: 0.03 mg/kg, p.o.), 
WAY-100,635 (WAY: 1 mg/kg, p.o.), or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 
hour prior to sociability testing. The effects of brexpiprazole on RI (A), duration of time spent 
around each stranger mouse (B) and exploratory behavior (C) during social recognition sessions. 
Values are the mean  S.E.M (n = 11-13). *p < 0.05, ***p < 0.001 compared with dizocilpine 
plus vehicle group, ###p < 0.001 compared with the dizocilpine plus brexpiprazole-treated group 
(A, one-way ANOVA, followed by post hoc Bonferroni test). *p < 0.05, ***p < 0.001 compared 
with stranger 1 mice (B, two-tailed paired t-test). N.S.: not significant. WAY-100,635 (WAY: 1.0 
mg/kg, p.o.), or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 hour prior to sociability 
testing. The effects of WAY-100,635 on RI (D), duration of time spent around each stranger 
mouse (E) and exploratory behavior (F) during social recognition sessions were shown. Values 
are the mean  S.E.M (n = 7). ***p < 0.001 compared with stranger 1 mice (E, two-tailed paired 
t-test). N.S.: not significant. 
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5. DISCUSSION 
The two major findings of this study are that the novel serotonin-dopamine 
activity modulator brexpiprazole, but not risperidone or olanzapine, improved social 
recognition deficits in mice after the administration of dizocilpine, and that 5-HT1A 
receptors are critical to this beneficial effect. Antipsychotic drugs, such as risperidone 
and olanzapine, are known to show limited efficacy in cognitive impairment, including 
social recognition in schizophrenia and depression (Sergi et al, 2007; Krakowski and 
Czobor, 2011; Suzuki et al, 2011; Remberk et al, 2012), despite improving various 
cognitive functions in rodent disease models (Wang et al, 2007; Gumuslu et al, 2013; 
Mutlu et al, 2011; 2012; Wolff and Leander, 2003). It is of considerable clinical 
importance to find new ways of improving social recognition deficits in patients with 
psychiatric diseases, such as schizophrenia and MDD, because of their huge negative 
impact on the social functioning of patients (Tandberg et al, 2011; Tse et al, 2013; 
Horan et al, 2012). There are noted discrepancies in antipsychotic drug effects between 
rodents and humans, increasing the need for further detailed clinical studies on the 
effects of brexpiprazole on social recognition in patients with psychiatric diseases. 
Social recognition testing is a paradigm capable of evaluating social recognition, 
based on the propensity of an individual mouse to spend more time with an unfamiliar 
mouse than with a familiar mouse (Riedel et al, 2009; Nakatani et al, 2009). In other  
cognitive tests performed in rodents, mice discriminate objects by vision in the novel 
objective recognition test, by hearing in the fear conditioning test and by odor in the 
social transmission food preference test (Hashimoto et al, 2005; 2007; Boix-Trelis et al, 
2007; Amann et al, 2010). However, since social recognition testing incorporates 
various factors such as visual, auditory and olfactory function and some tactile stimuli 
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needed for mouse sociability, this test provides a comprehensive evaluation of  
cognition in rodents, compared with other cognitive tests (Nadler et al, 2004; Moy et al, 
2004; 2007). Therefore, the social recognition test in mice may represent a translational 
rodent model for human social cognition, since the model utilizes multiple aspects of 
mice socialization. 
Here, we evaluated social recognition using an automated three-chambered 
apparatus system. This apparatus is capable of measuring the time and distance a subject 
mouse covers in approaching a novel mouse, thereby evaluating the subject’s 
motivation to interact with the novel mouse. Furthermore, this system can also measure 
exploratory behavior by producing a representative trace of locomotor activity. This 
means that effects on locomotion, such as, sedation by a drug, can be easily detected. 
Since stranger mice were isolated individually in a wire cage, the subject mouse could 
interact with a stranger mouse without attack or aversive stimuli. This makes the social 
recognition test in mice a potential tool for assessing the efficacy of new drugs on social 
recognition. 
We found that the 5-HT1A antagonist, WAY-100,635, reversed the effects of 
brexpiprazole on dizocilpine-induced social recognition deficits, indicating that 5-HT1A 
receptors are critical to brexpiprazole’s mechanism of action. A report suggests that 
5-HT1A receptor agonism is related to social recognition in rats (Millan et al, 2004). In 
addition, it is reported that 5-HT1A receptors are important in the action of other 
antipsychotic drugs (perospirone, aripiprazole, blonanserin), when tested in a 
phencyclidine-induced cognitive deficits model (Hagiwara et al, 2008; Nagai et al, 
2009; Horiguchi and Meltzer, 2012; 2013). In contrast, WAY-100,635 could alleviate 
cognitive deficits in monkeys after administration of dizocilpine (Harder and Ridley, 
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2000), suggesting pro-cognitive effect of 5-HT1A receptor antagonist. However, in this 
study, WAY-100,635 alone was no effect in social recognition in both dizocilpine-treated 
and vehicle-treated control mice. Further studies of the effects of 5-HT1A receptor 
agonists and antagonists on social recognition are needed. Previously, Sumiyoshi et al. 
(2001a; 2001b; 2007) reported that treatment with tandospirone (or buspirone), 5-HT1A 
receptor agonists, improved cognition including executive function and verbal learning 
in patients with schizophrenia, indicating a key role of 5-HT1A receptor in cognition in 
patients (Meltzer and Sumiyoshi, 2008; Sumiyoshi et al, 2013). Taken together, it seems 
that brexpiprazole can ameliorate cognitive deficits associated with NMDA receptor 
dysfunction, via its 5-HT1A agonistic activity. Further studies are needed to clarify the 
effects of other antipsychotic drugs with 5-HT1A agonistic activity, on social cognition 
in patients. 
Previous reports demonstrated that 5-HT1A receptor antagonists impair sociability 
in rodents, and that 5-HT1A receptor agonists improved sociability in the social 
interaction in rodents (File and Seth, 2003; Bruins Slot et al, 2005; Snigdha and Neil, 
2008; Gould et al, 2011). These findings suggest an important role of 5-HT1A receptors 
in social behaviors. A recent study showed that the rewarding properties of social 
interaction in mice require the coordinated activity of oxytocin and 5-HT1B receptor in 
the nucleus accumbens, which are implicated in the social cognitive dysfunction in 
patients with a number of psychiatric diseases (Dölen et al, 2013). Since brexpiprazole 
has a moderate affinity at 5-HT1B receptor (Ki = 32 nM) (Maeda et al, 2014a), it is 
possible that 5-HT1B receptor may, in part, be involved in the mechanisms of action of 
brexpiprazole on social recognition deficits. Nonetheless, further studies on the role of 
5-HT1B receptors in the mechanisms of action of brexpiprazole would be needed to 
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confirm this hypothesis. 
In conclusion, brexpiprazole ameliorated social recognition deficits in mice after 
administration of dizocilpine, and the 5-HT1A receptor antagonist WAY-100,635 
reversed the effects of brexpiprazole in this model. Our results imply that brexpiprazole 
could potentially serve as a therapeutic drug to treat social cognitive deficits in patients 
with schizophrenia and MDD. 
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III. CHAPTER 2 
Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on 
phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A 
receptors. 
 
1. ABSTRACT 
Brexpiprazole, a serotonin-dopamine activity modulator, is currently being 
tested in clinical trials as a new therapy for a number of neuropsychiatric diseases, 
including schizophrenia and major depressive disorder. Accumulating evidence suggests 
that 5-hydroxytryptamine (5-HT)1A receptors play a role in cognition. This study was 
undertaken to examine whether brexpiprazole, a novel drug with 5-HT1A receptor partial 
agonism, could improve cognitive deficits in mice, induced by repeated administration 
of the N-methyl-D-aspartate (NMDA) receptor antagonist, phencyclidine (PCP). 
Subsequent subchronic (14 days) oral administration of brexpiprazole (0.3, 1, or 3.0 
mg/kg/day) significantly attenuated PCP (10 mg/kg/day for 10 days)-induced cognitive 
deficits in mice, in a dose-dependent manner. The effects of brexpiprazole (3.0 mg/kg) 
were significantly antagonized by co-administration of the selective 5-HT1A receptor 
antagonist, WAY-100,635 (1.0 mg/kg), although WAY-100,635 alone was not effective 
in this model. These findings suggest that brexpiprazole can ameliorate PCP-induced 
cognitive deficits in mice via 5-HT1A receptors. Therefore, brexpiprazole could 
ameliorate cognitive deficits as seen in schizophrenia and other neuropsychiatric 
diseases. 
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2. INTRODUCTION 
Cognitive deficits are a core feature in people with schizophrenia, leading to both 
vocational and social disabilities (Coyle and Tsai, 2004; Freedman, 2003; Green et al, 
2004; Niitsu et al, 2012; Sumiyoshi et al, 2013; Yoshida et al, 2012b). Current evidence 
suggests that dysfunctional glutamatergic neurotransmission, via N-methyl-D-aspartate 
(NMDA) receptors is instrumental in the pathophysiology of schizophrenia (Coyle and 
Tsai, 2004; Hashimoto et al, 2004; 2005b; 2013; Heresco-levy and Javitt, 1998; Krystal 
et al, 1999; Javitt and Zukin, 1991; Javitt et al, 2012). Antagonists at the NMDA 
receptor, such as phencyclidine (PCP), are known to induce schizophrenia-like 
symptoms, including cognitive deficits in healthy subjects (Javitt and Zukin, 1991). This 
has led to the use of sub-chronic administration of PCP, as an animal model of cognitive 
deficits in schizophrenia (Fujita et al, 2008; Hagiwara et al, 2008; Hashimoto et al, 
2005a; 2006; 2007a; 2007b; Kunitachi et al, 2009; Javitt et al, 201; Jentsch and Roth, 
1999; Tanibuchi et al, 2009). In the novel object recognition test (NORT), PCP (10 
mg/kg/day for 10 days)-induced cognitive deficits were significantly ameliorated by 
subsequent, subchronic (14 days) doses of clozapine, but not haloperidol (Hashimoto et 
al, 2005a). These findings suggest that this reversal of PCP-induced cognitive deficits as 
measured by the NORT, may represent a potential animal model of atypical 
antipsychotic activity, in the amelioration of schizophrenia related cognitive deficits 
(Hagiwara et al., 2008; Hashimoto et al, 2005a; 2006; 2007a; 2007b; 2007c; Tanibuchi 
et al, 2009). 
Several lines of evidence show that 5-hydroxytryptamine (5-HT)1A receptors play 
a role in the pathophysiology of neuropsychiatric diseases including schizophrenia, and 
that 5-HT1A receptors are important targets for emotion and cognition (Bantick et al, 
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2001; Meltzer, 1999; Ogren et al, 2008; Sumiyoshi et al, 2013). Early evidence comes 
from findings that the density of 5-HT1A receptor binding is altered in the hippocampus 
and cerebral cortex of postmortem brains from schizophrenia patients (Burnet et al, 
1996; Gurevich and Joyce, 1997; Joyce et al, 1993; Lopez-Figueroa et al, 2004). A 
positron emission tomography study demonstrated increased cortical 5-HT1A receptor 
binding in drug-naive patients with schizophrenia (Borg, 2008; Tauscher et al, 2002). In 
contrast, other studies found no changes in 5-HT1A receptor density between 
schizophrenia and control samples (Bantick et al, 2004; Borg, 2008; Frankle et al, 2006). 
Second, atypical antipsychotic drugs, such as clozapine, ziprasidone, aripiprazole and 
quetiapine are all partial 5-HT1A receptor agonists, a property which may be relevant for 
their therapeutic actions in schizophrenia (Jordan et al, 2002; Newman-Tancredi et al, 
2001; Rollema et al, 2000; Sprouse et al, 1999). Third, Sumiyoshi and colleagues 
(2001a; 2001b) reported that adjunctive treatment with tandospirone, a selective 5-HT1A 
receptor agonist, induced improvements in some types of memory function, as well as 
cognitive performance in schizophrenia. Taken together, findings to date suggest 
5-HT1A receptor agonists as potential therapeutic drugs for treating cognitive deficits in 
schizophrenia (Meltzer and Sumiyoshi, 2008; Newman-Tancredi, 2010; Yoshida et al., 
2012b; Sumiyoshi et al, 2013). 
Brexpiprazole, 
7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one (Figure 1), is 
a potent partial agonist at human 5-HT1A (Ki = 0.12 nM), and dopamine D2L (Ki = 0.3 
nM), and an antagonist at 5-HT2A receptors (Ki = 0.47 nM)(Maeda et al, 2014). 
Considering the high affinity of brexpiprazole for 5-HT1A receptors, it would be of 
interest to study the effects of brexpiprazole on PCP-induced cognitive deficits in mice. 
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In the present study, using the NORT, we examined the effects of subchronic treatment 
(14 days) with brexpiprazole on cognitive deficits in mice, induced after repeated 
administration of PCP. Furthermore, we examined the role of 5-HT1A receptors in the 
action of brexpiprazole on the PCP-induced cognitive deficit model. 
 
 
3. EXPERIMENTAL PROCEDURES 
3.1. Animals 
Male ICR mice (6 weeks old) weighing 25–30 g were purchased from SLC Japan 
(Hamamatsu, Shizuoka, Japan). The mice were housed in clear polycarbonate cages 
(22.5×33.8×14.0 cm) in groups of 5 or 6 individuals under a controlled 12/12-h 
light–dark cycle (light from 7:00 AM to 7:00 PM), with the room temperature kept at 23 
± 1°C and humidity at 55 ± 5%. The mice were given free access to water and food 
pellets specifically designed for mice. The experimental procedure was approved by the 
Animal Care and Use Committee of Chiba University Graduate School of Medicine.  
3.2. Drugs 
PCP hydrochloride was synthesized in our laboratory at Chiba University. 
Brexpiprazole was provided from Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). 
WAY-100,635 maleate, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N- 
(2-pyridinyl)cyclohexanecarboxamide maleate salt), was purchased from Sigma-Aldrich 
Corporation (St. Louis, MO, USA). Other drugs were purchased from commercial 
sources. 
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3.3. Drug administration 
Saline (10 ml/kg/day) or PCP (10 mg/kg/day expressed as a hydrochloride salt) 
was administered subcutaneously (s.c.) for 10 days (once daily on days 1-5, 8-12) with 
no treatment on days 6, 7, 13, and 14 (Figure 5). The treatment schedule was designed 
in the manner of a previous PCP-induced cognitive deficit model (Hashimoto et al, 
2005a; 2006; 2007a; 2007b; 2007c). After the final administration of saline or PCP, 
vehicle (10 ml/kg/day; 0.5% methylcellulose), brexpiprazole (0.3, 1, or 3.0 mg/kg/day), 
brexpiprazole (3.0 mg/kg/day) plus WAY-100,635 (1 mg/kg/day), or WAY-100,635 (1 
mg/kg/day) alone was administered orally for 14 consecutive days (once daily on days 
15-28) (Figure 5). The dose (1 mg/kg) chosen for WAY-100,635 was selected because 
this dose was found to attenuate PCP-induced cognitive deficits via 5-HT1A receptor 
mechanisms in vivo (Hagiwara et al, 2008). 
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3.4. Novel object recognition test (NORT) 
The NORT was administered as previously reported (Hashimoto et al, 2005a; 
2006; 2007a; 2007b; 2007c). As shown in Figure 5, the training session of NORT was 
carried out 1 day (day 29) after the final administration of vehicle, brexpiprazole, or 
WAY-100,635. The apparatus for this task consisted of a black open-field box 
(50.8×50.8×25.4 cm). Before the test, mice were habituated to the box for 3 days. 
During the training session, two objects (various objects were used that differed with 
respect to shape and color, but that were similar in size) were placed in the box at a 
35.5-cm distance from each other, and in a symmetrical fashion, and each animal was 
Figure 5. Treatment schedule 
Saline (10 ml/kg/day) or PCP (10 mg/kg/day) was administered subcutaneously (s.c.) to mice for 
10 days (once daily, on days 1-5, 8-12). Three days (day 15) after the final dose of saline or PCP, 
vehicle (10 ml/kg/day), brexpiprazole (0.3, 1.0, or 3.0 mg/kg/day), brexpiprazole (3.0 mg/kg/day) 
plus WAY-100,635 (1.0 mg/kg/day), or WAY-100,635 (1.0 mg/kg/day) was administered orally, 
for 14 consecutive days (once daily on days 15-28). On days 29 and 30, the novel object 
recognition test (NORT) was carried out. 
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allowed to explore the interior of the box for 10 min (5 min x 2). The animals were 
considered to be investigating the object when the head of the animal was either facing 
the object and was located within an inch of the object, or if any part of the body, except 
for the tail, was touching the object. The time that the mice spent exploring each object 
was recorded. After the training session, the mice were immediately returned to their 
home cages, and the box and objects were cleaned with 75% ethanol to avoid any 
possible pheromonal cues. The retention test session was carried out 1 day after the 
respective training sessions. During each retention test session, each mouse was placed 
back into the same box it had previously encountered, but in which one of the two 
objects used during training had been replaced by a novel object. The mice were then 
allowed to freely explore the interior for 5 min, and the time spent exploring each object 
was recorded. Throughout the experiments, the objects were used in a counter-balanced 
manner in terms of their physical complexity. In order to measure memory performance, 
a preference index was used, i.e., the ratio of the amount of time the mouse spent 
exploring any one of the two objects (training session) or the novel object (retention 
session) to the total time spent exploring both objects.  
3.5. Statistical analysis 
The data are expressed as mean  S.E.M. Statistical analysis was performed using 
one-way analysis of variance (ANOVA) and the post hoc Bonferroni test. The P values 
of less than 0.05 were considered statistically significant. 
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4. RESULTS 
4.1. Effects of brexpiprazole on PCP-induced cognitive deficits in mice 
In the NORT, repeated administration of PCP (10 mg/kg/day for 10 days) led to 
cognitive deficits in mice, consistent with previous reports (Hashimoto et al, 2005a; 
2006; 2007a; 2007b). During the training session, there were no differences in 
exploratory preferences among the eight groups of mice (F (7, 96) = 0.444, p=0.872) 
(Figure 6A). Subsequent subchronic (14 days) administration of brexpiprazole 
significantly attenuated PCP-induced cognitive deficits in mice, in a dose-dependent 
manner. However, during the test session, ANOVA analysis revealed significant 
differences in the exploratory preferences among the eight groups (F (7, 96) = 15.52, p 
< 0.001) (Figure 6B). Post hoc Bonferroni test results indicated that subchronic dosing 
with brexpiprazole increased exploratory preferences in the PCP-treated group, in a 
dose dependent manner (Figure 6B). In addition, the effect of brexpiprazole (3.0 
mg/kg) on PCP-induced cognitive deficits was significantly antagonized by 
co-administration of the selective 5-HT1A receptor antagonist, WAY-100,635 (1.0 
mg/kg/day) (Figure 6B). Moreover, a 14 day dosing with WAY-100,635 (1.0 
mg/kg/day) alone did not reverse PCP-induced cognitive deficits in mice (Figure 6B). 
Neither did a 14 day dosing with brexpiprazole (3.0 mg/kg/day) alone alter exploratory 
preferences in control (saline-treated) mice (Figure 6B). 
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Figure 6. Effects of subchronic administration of brexpiprazole on PCP-induced 
cognitive deficits in mice  
Treatments were performed as shown in Figure 2. On days 29 and 30, the NORT was performed. 
Values are the mean  S.E.M (n = 10-16). N.S.: not significant, Brex: brexpiprazole, WAY: 
WAY-100,635. **P < 0.01, ***P < 0.001 compared with the PCP plus vehicle-treated group. 
###
P 
< 0.001 compared with the PCP plus brexpiprazole (3.0 mg/kg)-treated group. 
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5. DISCUSSION 
     This study found that brexpiprazole was able to ameliorate PCP-induced 
cognitive deficits in mice, via 5-HT1A receptors. Previously, we reported that 
PCP-induced cognitive deficits as demonstrated on the NORT could be improved by 
subsequent subchronic (14 days) administration of clozapine, but not haloperidol. This 
suggested that the reversal of these deficits may represent a potential animal model of 
atypical antipsychotic activity, for use in the ongoing investigations aimed at restoring 
cognitive deficits in schizophrenia (Hashimoto et al, 2005a). Given the role of 5-HT1A 
receptors in cognition (Bantick et al, 2001; Meltzer, 1999; Ogren et al, 2008; Yoshida et 
al., 2012b; Sumiyoshi et al, 2013), it is likely that brexpiprazole confers a beneficial 
effect on cognitive deficits in patients with neuropsychiatric diseases, such as 
schizophrenia. 
In an earlier report, we found that repeated dosing with PCP (10 mg/kg/day for 10 
days) significantly reduced the density of 5-HT1A receptors in mouse hippocampus, 
although the precise mechanisms underlying this action are currently unknown 
(Hagiwara et al., 2008). Furthermore, we found that repeated PCP administration 
significantly altered the response to 8-OH-DPAT (8-hydroxy-2-(dipropylamino)tetralin 
hydrobromide: a 5-HT1A agonist)-induced hypothermia in mice (Hagiwara et al., 2008). 
We also reported that perospirone, an antipsychotic drug with 5-HT1A receptor agonism, 
could attenuate PCP-induced cognitive deficits via 5-HT1A receptors (Hagiwara et al., 
2008). Together, these findings imply that altered 5-HT1A receptor function resulting 
from repeated PCP treatment may add to the dysregulation of glutamatergic 
neurotransmission in the brain. 
Sumiyoshi et al. (2001a; 2001b) reported that adjunctive treatment with the 
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5-HT1A receptor agonist, tandospirone, improves certain types of memory function, as 
well as cognitive performance in patients with schizophrenia. In a later study, 
Sumiyoshi et al. (2007) also reported that adjunctive treatment with buspirone, a widely 
available 5-HT1A receptor agonist, significantly enhanced attention compared with the 
placebo control group, highlighting a possible benefit for buspirone augmentation of 
atypical antipsychotic drugs, to enhance attention. These findings suggest that 5-HT1A 
receptor agonists, including brexpiprazole, may be useful for treating cognitive deficits 
in schizophrenia. 
Cognitive deficits are well documented in patients with other neuropsychiatric 
diseases, including major depressive disorder (Porter et al., 2003; Hindmarch and 
Hashimoto, 2010; Hasselbalch et al., 2011; Yoshida et al., 2012a), bipolar disorder 
(Harvey et al., 2010; Bourne et al., 2013), and substance abuse (Dean et al., 2013). In 
some ways, rodent NORT performance is analogous to human declarative (episodic) 
memory, one of the seven cognitive domains impaired in patients with schizophrenia 
(Rajagopal et al., 2014). It is therefore possible that brexpiprazole could be an equally 
useful therapeutic drug in these patients. 
     In conclusion, our findings showed that PCP-induced cognitive deficits in mice 
could be improved by subchronic treatment with brexpiprazole. Therefore, 
brexpiprazole which acts as a 5-HT1A receptor partial agonist, could potentially serve as 
a therapeutic drug for the treatment of cognitive deficits in patients with schizophrenia 
and other neuropsychiatric diseases.  
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IV.  CONCLUSION 
Brexpiprazole improved social recognition deficits impaired by dizocilpine in 
social recognition test. This effect was antagonized by 5-HT1A receptor antagonist 
WAY-100,635, suggesting that brexpiprazole can improve social recognition deficits 
impaired by N-methyl-D-aspartate antagonist via 5-HT1A agonistic activity. Additionally, 
brexpiprazole improved cognitive deficits impaired by PCP in NORT. This effect was 
also antagonized by WAY-100,635, suggesting that brexpiprazole can improve cognitive 
deficits impaired by N-methyl-D-aspartate antagonist throughout 5-HT1A agonistic 
activity. Taken together, these studies suggest that brexpiprazole has ability to improve 
cognitive deficits in animal models of psychiatric disorders. Therefore, brexpiprazole 
would have beneficial effects for cognitive deficits in the patients with a number of 
psychiatric disorders.  
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